Search Results
Sep 10, 2026, 15:40 ET Who Decides Where the Money Goes? In Its 50th Year, Liberty Hill Backs 17 Community-Led Organizations Building What Comes Next
the Community Funding Board (CFB), an innovative participatory grantmaking model grounded in the belief that those closest to community issues and solutions should help shape funding decisions. Bringing together movement leaders, donors, and philanthropic partners, the CFB is a core part of the Foundation's
More news about: Liberty Hill Foundation
Aug 13, 2026, 10:31 ET Bronchiectasis Market is Expected to Surge at a CAGR of 15% by 2036, Owing to the Launch of DPP1/CatC Inhibitors, Therapeutic Phage Cocktails, Nebulized Mucoactive Agents, and Other Novel Mechanisms | DelveInsight
NCFBMicrobiology of NCFB Patients Total Diagnosed Prevalent Cases of CFBGender-specific Diagnosed Prevalent Cases of CFB Age-specific Diagnosed Prevalent Cases of CFB Microbiology of CFB Patients Total treated cases of Bronchiectasis
More news about: DelveInsight Business Research, LLP
Aug 11, 2026, 06:30 ET DarioHealth Reports Second Quarter 2026 Financial Results
https://viavid.webcasts.com/starthere.jsp?ei=1767650&tp_key=4cfb9bb10dParticipants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the
More news about: DarioHealth Corp.
Aug 03, 2026, 06:30 ET DarioHealth to Report Second Quarter 2026 Results on Tuesday, August 11, 2026
https://viavid.webcasts.com/starthere.jsp?ei=1767650&tp_key=4cfb9bb10dParticipants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the
More news about: DarioHealth Corp.
Jun 23, 2026, 09:17 ET Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications
currently being evaluated in a Phase I clinical trial in China. HSK39297 is a best-in-class potential once-daily (QD) CFB inhibitor. Two NDA applications for PNH have been submitted in China, while several additional indications are advancing
More news about: Haisco Pharmaceutical Group Co., Ltd.
Apr 20, 2026, 08:00 ET Argo Biopharma Doses First Patients in Phase II Clinical Trials of siRNA Therapy BW-40202
co-founder and CEO of Argo Biopharma.BW-40202 is an siRNA therapeutic that targets CFB mRNA in the liver. It utilizes an RNA interference (RNAi) mechanism to suppress CFB expression, thereby reducing serum CFB protein levels and inhibiting complement alternative pathway (CAP) activity. In preclinical
More news about: Argo Biopharmaceutical Co., Ltd
Feb 12, 2026, 23:36 ET Pepperstone dominiert die Global Forex Awards: Vier große Siege zum Auftakt des Jahres 2026
Foto - https://mma.prnewswire.com/media/2871580/CFB_Awards_4trophies.jpgLogo - https://mma.prnewswire.com/media/2871579/Pepperstone_Logo.jpg
More news about: Pepperstone Financial Services LLC
Feb 02, 2026, 09:57 ET Pepperstone domina o Global Forex Awards: quatro vitórias importantes marcam o início de 2026
Foto - https://mma.prnewswire.com/media/2871864/CFB_Awards_4trophies.jpgLogo - https://mma.prnewswire.com/media/2871579/Pepperstone_Logo.jpg
More news about: Pepperstone Financial Services LLC
Feb 02, 2026, 09:55 ET Pepperstone domina los Global Forex Awards: cuatro triunfos importantes dan inicio al 2026
Foto - https://mma.prnewswire.com/media/2871866/CFB_Awards_4trophies.jpgLogo - https://mma.prnewswire.com/media/2871579/Pepperstone_Logo.jpg
More news about: Pepperstone Financial Services LLC
Jan 29, 2026, 11:13 ET Pepperstone domineert de Global Forex Awards: Vier grote overwinningen luiden 2026 in
Foto - https://mma.prnewswire.com/media/2871580/CFB_Awards_4trophies.jpgLogo - https://mma.prnewswire.com/media/2871579/Pepperstone_Logo.jpg
More news about: Pepperstone Financial Services LLC
Jan 28, 2026, 23:00 ET Pepperstone Dominates Global Forex Awards: Four Major Wins Kick Off 2026
Photo - https://mma.prnewswire.com/media/2871580/CFB_Awards_4trophies.jpgLogo - https://mma.prnewswire.com/media/2871579/Pepperstone_Logo.jpg
More news about: Pepperstone Financial Services LLC
Dec 18, 2025, 20:28 ET CEIS | POWER APPOINTS KAREN SERCEY AS BUSINESS DEVELOPMENT DIRECTOR
full-service offerings across critical boiler systems:Boiler Expertise: Targeting Utility & Industrial Boilers, HRSG, CFB, BFB, Waste Heat, and Cyclone systems.Equipment Reliability: through equipment rebuilds, boiler mill programs, and failure analysis/condition
More news about: CEIS | Critical Energy Infrastructure Services
Dec 03, 2025, 02:53 ET Valmet in key role to decarbonize Fortum's Zabrze combined heat and power plant in Poland
deliver circulating fluidized bed (CFB) boiler fuel conversion for Fortum Zabrze plant in Poland (photo Fortum).Details about Valmet's deliveryValmet is the main contractor for the modifications in the existing circulating fluidized bed (CFB) boiler from coal to biomass. The
More news about: Valmet Oyj
Nov 17, 2025, 04:41 ET Valmet's new waste-to-energy boiler to help Cheng Loong Corporation in Taiwan to decarbonize Houli mill's energy production
fuel flexibility to use both industrial and municipal waste streams (RDF, SRF and TDF) as well as biomass as fuel. The Valmet CFB Boiler utilizes circulating fluidized bed (CFB) technology, which, when operated with high steam parameters, enables significantly higher electricity production from waste fuels
More news about: Valmet Oyj
Nov 05, 2025, 17:31 ET Rheumatoid Arthritis Market to Surge by 2034 as Next-Generation Biologics and JAK Inhibitors Gain Traction | DelveInsight
AstraZeneca's AZD6912 is a small interfering RNA (siRNA) therapy targeting human Complement Factor B (CFB), a critical component of the alternative complement pathway. By suppressing hepatic CFB expression, AZD6912 aims to reduce systemic complement activation, thereby mitigating inflammation and tissue
More news about: DelveInsight Business Research, LLP
Oct 25, 2025, 11:00 ET BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
were observed to 24 weeks, with mean (SD) change from baseline (CfB) at Week 24 of −1.9 (2.0).5 SF-36 PCS scores improved to Week 24 (mean [SD] CfB: +4.6 [7.9]), as did PGADA scores (mean [SD] CfB: −17.5 [23.8]).5 At Week 2, mean (SD) CfB in PsAID-12 total score and PGADA score were -0.8 (1.6)
More news about: UCB
Sep 18, 2025, 16:01 ET Scholastic Reports Fiscal 2026 First Quarter Results
https://register-conf.media-server.com/register/BI3cfb64159a51425fb55ed1b1e65f9458, which will provide dial-in details. To avoid delays, participants are encouraged to dial into the conference
More news about: Scholastic Corporation
Sep 15, 2025, 08:00 ET Argo Biopharma Receives IND Approval from NMPA for Phase II Clinical Trial of siRNA Therapy, BW-40202, for the Treatment of PNH
co-founder and CEO of Argo Biopharma. BW-40202 is an siRNA therapeutic that targets CFB mRNA in the liver. It utilizes an RNA interference (RNAi) mechanism to suppress CFB expression, thereby reducing serum CFB protein levels and inhibiting CAP activity. In preclinical studies, BW-40202 demonstrated
More news about: Argo Biopharmaceutical Co., Ltd.